Prospective, Open Label, Pilot Study of Safety and Efficacy of Triple Anti-Viral Therapy with Pegylated Interferon, Ribavirin, and Boceprevir in Patients with Genotype 1 Chronic HCV with End Stage Renal Disease (ESRD) on Hemodialysis
||Merck & Co. Inc
||Male and Female Patients
|U.S. Govt. ID:
||Theresa Lukose: 212-305-3839 / firstname.lastname@example.org
The purpose of this study is to determine how safe and effective using three medications (pegylated-interferon, ribavirin and boceprevir) are in curing HCV in patients with end stage kidney disease on hemodialysis. Participants will be prescribed these three medications and will be followed closely through treatment, then for 6 months afterwards. During treatment, participants will need to come to clinic every 2 weeks through week 12, and then monthly until the end of treatment so that their doctor can monitor their progress on this treatment. Once participants have completed treatment, they will need to come in 1 month, 3 months and 6 months after the end of treatment.
This study is closed
Elizabeth Verna, MD
|Are you between 18-65 years of age?